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Gastro-oesophageal reflux disease (GORD) 
is well entrenched in the clinician’s mind. 
But, is it a spurious or artificial concept and 
what do we actually know about it? There 
are just too many things that don’t add up.
When communicating with patients most 
doctors still cite the traditional concepts 
relating to GORD, that it is related to one 
or more of the following: ‘excessive acid’ 
into the oesophagus; ‘failure of the valve’ at 
the gastro-oesophageal junction; ‘delayed 
gastric emptying’; and ‘damage’ at the 
lower oesophagus. Regrettably, none of 
these holds true. And, as clinicians who 
base our explanatory models on what we 
construct for our patients we are almost 
certainly on the wrong track. 
gord is not normally related to 
excessive acid
The ‘excessive acid’ explanation is clearly 
flawed as acid-secretion levels are normal 
in people with GORD (except rarely, in 
the Zollinger–Ellison syndrome), lower 
oesophageal sphincter pressures are not 
different (although periods of relaxation may 
be more frequent) and there seems to be no 
consistent evidence about delayed gastric 
emptying in the majority of sufferers. Worse 
still, in terms of explanatory models, there 
is no consistency from symptom association 
analyses when symptoms are evaluated 
against pH monitoring.
the imPact of acid-suPPression 
drugs
The increase in the prevalence of GORD 
coincided with the era of acid suppression 
drugs. The mid-1980s saw the widespread 
use of the histamine H2 receptor antagonists 
in volumes far greater than were anticipated 
for ulcer disease alone. The more powerful 
acid suppressors, the proton-pump inhibitors 
(PPIs), were also indicated initially for peptic 
ulcers but have become the mainstay for 
GORD. Ironically, GPs were criticised for 
prescribing them in patients without ulcers. 
The concept of GORD became entrenched in 
the Montreal Consensus in 20061 only after 
many years of acid-suppression therapy in 
clinical practice. Here, GORD was defined as:
‘... a condition that develops when the reflux 
of stomach contents causes troublesome 
symptoms and/or complications.’1 
A wonderfully handy concept, this 
covered all situations from someone with 
an endoscopic lesion (albeit even without 
symptoms) to one who had symptoms but 
no other findings. In a near-perfect model of 
the consensus approach we encompassed 
both symptoms and findings with reflux as 
the common factor.
First, symptoms. The cardinal symptoms 
ascribed to GORD are heartburn and 
regurgitation. These seem convenient and 
well encapsulated within our thinking. But, 
how reliable and consistent are these? In 
the Diamond study,2 the authors, many 
of whom were part of the initial Montreal 
Consensus, critically assessed the value 
of symptoms in patients judged as having 
GORD. The results were startling as well 
as revealing: that GORD was considered 
to be present in only 65% of patients so 
diagnosed initially and that only 49% of 
patients with GORD selected heartburn or 
regurgitation as their most troublesome 
symptom. Therefore the value of these 
symptoms is questionable.
is the PPi test worthwhile?
Furthermore, the use of esomeprazole, a 
PPI, in therapeutic doses proved neither 
sensitive nor specific for the diagnosis of 
GORD and a 2-week course of this did not 
add to diagnostic precision.2 This clearly 
challenged the previously-held adage that a 
PPI response test could help to distinguish 
patients with GORD from other conditions. 
In pragmatic terms a positive result merely 
indicates that the patient has improved, 
rather than indicating what the problem 
happens to be, and there is the placebo 
effect to be considered. This reflects the 
common experience of GPs who are used 
to variable responses to PPIs for what 
they perceive to be GORD. Studies confirm 
that the majority of patients on long-
term PPIs continue to suffer moderate to 
severe symptoms.3 The corollary to this is 
the perverse therapeutic mindset which 
assumes that either the patient has been 
non-compliant or that the doses and timing 
of the acid suppression agents need to be 
altered.
Against this confusing backdrop, what 
are we actually treating? Mainie et al in a 
seminal paper on GORD management,4 
reported on patients taking twice-daily PPIs. 
Of the 200 patients in their study, 86% had 
continuing symptoms. Using impedance 
pH measurements they demonstrated 
that only 8% of them had acid reflux, 35% 
had non-acid reflux, and that in 57% their 
symptoms were not related to reflux at 
all. These findings, since confirmed, shed 
new light on the origins of so-called GORD 
symptoms, indicating that at least some 
patients have an aetiology not related to 
reflux per se, and also not related to acid.
Meanwhile, the prevalence of GORD as 
we understand it is rising. The Norwegian 
HUNT Research Centre reports a 31% 
increase in the prevalence of gastro-
oesophageal symptoms over 10 years to 
2009 with a corresponding 47% increase in 
the frequency of symptoms.5 Startlingly, the 
increase is strongly marked in those aged 
>60 years, a stage at which possible cancer 
is an issue. 
challenges and new concePts
A number of new concepts have 
emerged which challenge our traditional 
understanding of GORD. Firstly, the 
discovery of the acid pocket, demonstrated 
by Beaumont et al,6 whereby acid is noted 
to accumulate after a meal above the 
stomach contents, below the gastro-
oesophageal junction and, in those with 
a hiatus hernia, into the hernia sac. 
These predispose to acid reflux and pH 
pull-through studies, which measure 
acid exposure at different parts of the 




“... the spectrum of lesions and causes ranges 
hierarchically from erosive oesophagitis, non-erosive 
reflux disease, acid sensitive oesophagus to functional 
heartburn, with the effectiveness of acid suppression 
reducing in that order.”
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“It is likely that no such entity as GORD actually 
exists.”
in oesophageal pH in such patients.7 These 
offer an explanation for postprandial 
symptoms in some patients and set up 
alternative therapeutic possibilities: 
whereas acid suppression therapy may 
not abolish all the acid, other agents such 
as alginates may offer the opportunity of 
mucosal protection. Such treatment could 
be an adjunct to PPIs or an alternative 
where acid suppression is not needed to 
manage endoscopic oesophagitis.
A further concept that may explain the 
inconsistencies in our construct of GORD 
is a better understanding of the mucosal 
integrity of the lower oesophagus. Impaired 
mucosal integrity may be the result from 
repeated reflux episodes and studies 
have shown that slow recovery after acid 
challenge is associated with increased 
oesophageal sensitivity.8 Admittedly while 
these concepts remain acid related, they 
may benefit patients not responding to 
conventional therapies, such as through the 
development of mucosal protective agents.
overlaP of causes and lack of 
sPecificity of symPtoms
The background to abdominal problems, 
as GPs know, is the overlap of symptoms 
from different causes, including functional 
gastrointestinal disorders. The label of 
functional heartburn has been only sparsely 
applied to date, with its implications of 
visceral hypersensitivity and associations 
with IBS. This may be clarified as the outputs 
of the Rome Foundation for Functional GI 
Disorders progress to their next iteration. 
For now, the spectrum of lesions and 
causes ranges hierarchically from erosive 
oesophagitis, non-erosive reflux disease, 
acid-sensitive oesophagus to functional 
heartburn, with the effectiveness of acid 
suppression reducing in that order.9 
People with ‘GORD’ symptoms clearly 
represent a heterogeneous population 
with complex and differing underlying 
mechanisms for the problem. A clinical 
diagnosis and acid suppression alone both 
have marked limitations, which the clinician 
needs to recognise. Matching the right 
approach for the individual patient is more 
crucial than trying to fit people within a 
model which, now, is looking less practical 
than some years ago. 
is gord a real entity?
It is likely that no such entity as GORD actually 
exists. It is more likely that a common 
group of symptoms can be ascribed to 
different causes, even non-gastrointestinal. 
An effective therapeutic approach in this 
complex area requires a tailored regimen; 
diet and weight advice initially, a possible 
trial of acid-suppression drugs, normally 
PPIs, postprandial alginates, and a careful 
evaluation of the level of success. PPIs 
alone are not the answer for most sufferers 
and a re-evaluation of the diagnosis and 
underlying reasons for the symptoms may 
require a completely different approach: 
one geared to functional problems or non-
GI causes. Some patients with especially 
troublesome symptoms may need referral 
for sophisticated testing such as pH 
monitoring and manometry to try to pin 
down the cause of the symptoms but the 
returns are likely to be low. 
The truth is that what was thought to 
be a straightforward condition related to 
acid reflux has turned out to encompass 
complex issues, for which there is often no 
answer. And, don’t forget, cardiac and other 
causes such as cancer, for the symptoms. 
Old paradigms die hard.
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